Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial*

Overview of attention for article published in Diabetes Care, December 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 2 news outlets
blogs: 1 blog
policy: 2 policy sources

twitter: 67 X users
facebook: 1 Facebook page

Citations

dimensions_citation: 386 Dimensions

Readers on

mendeley: 314 Mendeley

Summary News Blogs Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 public wall post.

Dr. Karl Nadolsky, 15 Dec 2017

Semaglutide, from Novo Nordisk will be available soon and a good addition to the arsenal for combating #obesity-driven type 2 #di…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.